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Goji juice and other Goji-derivedproducts are becoming increas-
ingly popular in Europe and North
America. They are sold as food sup-
plements or “super food”, mostly via
the Internet. Goji is the name given
since the beginning of this century to
Lycium barbarum and a closely related
species, L. chinense. The fruit has a
long tradition of use as food and tradi-
tional medicine in Asian countries but
reports on its consumption in Europe
up to now have been only anecdotal.
Health claims recently propagated
cover almost all imaginable therapeutic
indications. However, the main focus is
on age-related conditions. Specifically,
Goji is often praised as quasi-miracu-
lous cure for well-being and longevity. 
In order to critically assess the po-
tential of Goji and distinguish between
hype and potential health benefits, we
have reviewed the current scientific
knowledge of the fruit’s constituents,
pharmacology and toxicology. The
market situation and legal issues are
also briefly addressed. Since only L.
barbarum plays a significant role in
commercial products outside Asia, we
have focussed on this species. In addi-
tion, selected information is given on L.
chinense to provide a comprehensive
picture of Goji fruit. 
Botanical aspects
and origin of Goji
Lycium barbarum L. (synonym L. hal-
milifolium Miller) (Solanaceae) is a
shrub one to three meters high. The
oblong, orange to dark red berries
Background: In recent years, products derived from Goji berries (Lycium barbarum) have
become increasingly popular in Europe and North America. Numerous products are sold mostly
via the internet. On the novel food market, the fruit is sometimes referred to as a “superfruit”;
in particular, Goji is praised as cure for longevity and well-being. In Asia, the fruit of L. barbarum and
the closely related species L. chinense have in fact a long tradition of use as a food and traditional
medicine. In Europe, however, reports on its consumption up to now are anecdotal. Objective:
To provide an overview of the current knowledge on constituents, pharmacology and toxicology
of Goji and Goji-derived products. In addition, legal issues and the market situation are briefly
addressed. Method: Systematic analysis of scientific literature on Goji fruit found in major elec-
tronic data bases. Results: A range of potentially beneficial pharmacological activities, particularly
antioxidative and immunomodulatory properties, have been detected both in vitro and in vivo.
Proteoglycans and carotenoids appear to be the pharmacologically relevant compounds.
Preliminary data suggest some potential for the prevention of age-related diseases, including neu-
rodegenerative diseases, atherosclerosis and diabetes. However, clinical data are essentially lack-
ing. On the toxicological level, the fruit appears nontoxic but a case of possible drug interaction has
been reported Conclusions: Goji fruit deserves further investigation to assess its real potential, in
particular in the context of age-related diseases. At the same time, there is no scientific evidence
to support claims made for Goji juice as a “cure-all” and quasi-miraculous potion for longevity.
While the fruit can be considered safe, some caution is advised with regard to possible drug inter-
actions as well as products of unknown or ill-defined origin.  
Key words: Lycium barbarum, Solanaceae, Goji, novel food, constituents, health claims, safety,
antioxidant, immunomodulation, anti-aging, traditional Chinese medicine
Goji-Saft, ein neuer Wundertrank für Langlebigkeit und Wohlbefinden? Eine
Übersicht zu Inhaltsstoffen, Pharmakologie, Wirkversprechen und Nutzen
Hintergrund: Produkte auf der Basis von Goji Beeren (Lycium barbarum) wurden in letzter Zeit
immer beliebter in Europa und Nord Amerika. Zahlreiche Produkte werden über Internet vertrie-
ben. Auf dem Novel Food-Markt wird die Frucht oft als „Superfrucht“ bezeichnet und insbe-
sondere als „Wundermittel“ für einen guten Gesundheitszustand und Langlebigkeit angepriesen.
Die Frucht von L. barbarum und der nahe verwandten Spezies L. chinense haben in Asien eine
lange Tradition als Nahrungsmittel und in der traditionellen Medizin. Dagegen sind Berichte über
den bisherigen Konsum von Goji-Beeren in Europa von anekdotischer Natur. Zielsetzung: Es soll
eine Übersicht gegeben werden über den derzeitigen Kenntnisstand betreffend Inhaltsstoffe,
pharmakologische Untersuchung und toxikologische Daten. Methoden: Systematische Auswer-
tung der wissenschaftlichen Literatur zur Goji-Frucht aus den gängigen elektronischen Daten-
banken. Ergebnisse: Eine Reihe von potenziell bedeutsamen pharmakologoischen Aktivitäten
einschliesslich antioxidativer und immunmodulatorischer Eigenschaften wurden in verschiedenen
Modellen nachgewiesen. Massgeblich für die Aktivität scheinen Proteoglykane und Carotinoide
zu sein. Vorläufige Daten deuten auf ein gewisses Potenzial zur Vorbeugung von altersbedingten
Krankheiten hin, unter anderem von neurodegenerativen Erkrankungen, Atherosklerose und Dia-
betes. Klinische Daten fehlen aber weitestgehend. Toxikologische Untersuchungen belegen, dass
die Frucht ungiftig ist. Ein Fall von möglicher Arzneimittelinteraktion wurde aber dokumentiert.
Schlussfolgerungen: Goji verdient sicherlich weitere Untersuchungen, um die klinische Bedeu-
tung der nachgewiesenen pharmakologischen Aktivitäten zu substantivieren, insbesondere bei
altersbedingten Krankheiten. Auf der anderen Seite fehlen jegliche wissenschaftliche Belege,
welche die überzogenen Ansprüche als “Wundermittel“ unterstützen. Während die Frucht toxi-
kologisch unbedenklich scheint, ist eine gewisse Vorsicht geboten im Hinblick auf mögliche me-
dikamentöse Interaktionen und bei Produkten unbekannter oder zweifelhafter Herkunft.
Schlüsselwörter: Lycium barbarum, Goji, Solanaceae, Novel Food, Inhaltsstoffe, Antioxidans, Im-
munmodulation, Anti-Aging, traditionelle chinesische Medizin
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measure up to 2 cm and possess a bit-
ter to sweet taste (Fig. 1). Traditional
vernacular names of the plant are box-
thorn (German: gemeiner Bocksdorn),
matrimony wine or wolfberry [1]. In re-
cent years, the plant, and by extension,
the fruit itself have been increasingly
designated as Goji, a name derived
from the Chinese “Gouqi”. As already
mentioned, Goji is also used to describe
a closely related species L. chinense
Miller. The fruits of these two Lycium
species possess a highly similar anatomy
and tissue structure, and differentiation
based on morphological and histologi-
cal analyses are very difficult. Reliable
distinction requires molecular tech-
niques such as RAPD (random ampli-
fied polymorphic DNA) analyses [2]. 
The original habitat of L. barbarum
is not definitively established but is
probably to be found in the Mediter-
ranean Basin [3]. Meanwhile, the plant
is widely distributed in warm regions
of the world, in particular in the
Mediterranean area, Southwest and
Central Asia. It is also cultivated in
North America and Australia as hedge
plant [1]. Commercially significant cul-
tivation of Goji is only found in China.
The majority of commercially produced
wolfberries comes from plantations of 
L. barbarum in the Ningxia Hui Region
in north-central China and the Xinjiang
Uyghur Region in Western China. In
China, the production of Goji berries
yielded 95’000 tons in 2004, generat-
ing US$ 120 millions of revenue [4]. 
Traditional use of Goji
Goji berries are a very popular ingre-
dient in Chinese cuisine. They are con-
sumed in soups, as porridge with rice
and added to numerous meat and veg-
etable dishes. The fruits are harvested
from August to October. In Ningxia, the
main production center of Goji, the
harvest is annually celebrated with a
festival in August. The fruits are usu-
ally dried but they may also be con-
sumed fresh like the young leaves which
are a valued vegetable.  
Lycii fructus (Gou Qi Zi) is listed in
the Chinese Pharmacopeia. While only
the fruit of L. barbarum is officinal [5],
both species, L. barbarum and L. chi-
nense, have been used for more than
2000 years in Traditional Chinese Med-
icine with early records tracing back to
Tang Dynasty (1000–1400 AD) [6]. The
berries are eaten raw, drunk as juice,
wine or tea. They can also be processed
to tinctures, powders and tablets. The
recommend dosage of dried berries
varies between 5 and 12 g [7,8]. Goji
berries are used in Traditional Chinese
Medicine as mild Yin tonic, enriching Yin
in liver, kidneys and moistening lung Yin.
Indications derive from its Yin-nour-
ishing effect (Table 1). They include
blurry vision and diminished visual
acuity, infertility, abdominal pain, dry
cough, fatigue and headache [7–10]. The
berries are also praised in folk medicine
to increase longevity [11] and against
prematurely gray hair [9]. Besides
China, Goji berries are part of the med-
icinal tradition in other Asian countries
including Vietnam [12], Korea and
Japan.
Constituents
Polysaccharides represent quantitatively
the most important group of sub-
stances in the fruit of L. barbarum.
Quantitative data in literature diverge
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Tab. 1. Indications for Lycii fructus in the traditional Chinese medicine [7–9]
Liver and kidney Yin deficiency
■ Dizziness, blurry vision, diminished visual acuity
■ Nocturnal emission
■ Night sweating
■ Infertility, impotency
■ Soreness and weakness of the lower back and knees
■ Prevention of premature aging, prematurely grey hair
■ Fatigue, to replenish vital essence
■ Wasting and thirsting disorder (diabetes)
■ Blood deficiency (Anaemia)
Lung Yin deficiency
■ Dry cough
■ Cough with blood or blood streaks
Fig. 1. Lycium barbarum (photo: Prof. Jingui Shen).
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considerably. A yield of 23% based on
the dried fruit was obtained after opti-
mization of extraction conditions [13].
The polysaccharide fraction consists of
a complex mixture of highly branched
and only partly characterized polysac-
charides and proteoglycans, which is
often referred to as Lycium barbarum
polysaccharides or LBP. The glycosidic
part accounts in most cases for about
90–95% of the mass and consists of
arabinose, glucose, galactose, mannose,
rhamnose, xylose and/or galacturonic
acid [13–16].    
A second major group of metabolites
are the carotenoids which are at the
same time responsible for the fruit’s
red color. The content of carotenoids
increases during the ripening process.
Zeaxanthin dipalmitate is the predom-
inant constituent [17] representing
56% of the total carotenoids in the fruit
of L. barbarum and 49% in L. chinense
[18]. β-Cryptoxanthin monopalmitate,
zeaxanthin monopalmitate, a small
amount of free zeaxanthin and β-
carotene are also present [19]. The
fruits further contain vitamins, in par-
ticular riboflavin, thiamin and ascorbic
acid, together with a glucosylated pre-
cursor of the latter [20,21]. The con-
tent of vitamin C of 42 mg/100g is com-
parable to that of fresh lemon fruits.
Flavonoids are another important class
of compounds. The content of total
flavonoids is approximately 1.5g/kg of
fruit [22]. Among these, rutin has been
detected in hydroalcoholic extracts [22]
and the aglycones myricetin, quercetin
and kaempferol have been identified
after hydrolysis [23]. The essential oil
and fatty acids of L. barbarum have
been analyzed by GC-MS and hexade-
canoic acid, linoleic acid, β-elemene,
myristic acid and ethylhexadecanoate
have been identified as the main con-
stituents [24]. The fruit contains 1–2.7%
free amino acids with proline as major
constituent. The non-proteinogenic
amino acids taurine and γ-aminobu-
tyric acid as well as betaine (trimethyl-
glycine) are also contained in the fruit
[25,26]. Finally, some miscellaneous
compounds have been isolated includ-
ing β-sitosterol and its glucoside daucos-
terol, scopoletin, p-coumaric acid, the
dopamine derivative lyciumid A and L-
monomenthyl succinate [27]. The com-
position of the fruit of L. chinense ap-
pears to be similar. As in L. barbarum,
polysaccharides, carotenoids and flavo-
noids are the typical metabolites. In ad-
dition, the isolation of two cerebrosides
[28] and three pyrole derivatives [29]
with hepatoprotective properties is to
be mentioned. The identification of a
series of sterols, tocopherols, choloro-
genic and neochlorogenic acids [30]
has been reported.
There have been some controversies
about the atropine content of the fruits.
In 1989, a content of 0.95% of atropine
was reported for a fruit sample col-
lected in India [31]. This finding ap-
pears highly doubtful and does not fit
with the widespread consumption of
the fruits and lacking reports of appar-
ent toxicity. Recently, a systematic in-
vestigation of Goji berries from various
provenances has been undertaken with
HPLC-MS [32]. Only traces of atropine,
maximally 19 ppb (w/w), were detected
in the analyzed samples. 
Pharmacological properties 
Pharmacological investigations have
been mostly performed with an aque-
ous extract or more or less purified
polysaccharide fractions. Studies fo-
cussed on antioxidative and immuno-
modulatory properties in the context of
age-related diseases including athero-
sclerosis, neurodegeneration and dia-
betes [33]. Antioxidant properties have
been detected in various in vitro and
in vivo assays. The activity has been
mainly attributed to the flavonoids [23]
and polysaccharides (LBP) [34]. The
mechanisms of action involve for both
groups of compounds reducing capac-
ity, metal ion chelation and radical
scavenging activity [23]. Betain might
also contribute to the antioxidant ac-
tion [35]. Of particular interest is the
activity of the polysaccharides, since
these constituents are relatively char-
acteristic of Goji fruit. Polysaccharides
extracted from the fruit exhibited an-
tioxidant activity in the β-carotene/
linoleic assay as well as radical scav-
enging activity towards the superoxide
anion and reducing capacity which
were similar to those of the synthetic
antioxidant BHT [34]. They also strongly
inhibited the AAPH (2,2'-azobis (2-
amidinopropane) dihydrochloride)-in-
duced hemolysis of erythrocytes. The
glycoconjugate LbGp5B inhibits LDL
oxidation in vitro [14]. LBP showed pro-
tective effects on heat-induced damages
in rat testes in vivo and H2O-induced
oxidative damage in mouse testicular
cells in vitro [36]. In rabbits fed with
1.5% cholesterol over ten weeks, celiac
injection of LBP reduced the increase
of triglyceride, increased the ratio of
HDL-cholesterol to total cholesterol and
improved oxidation markers [37]. Oral
administration of LBP exhibited pro-
tective effects on streptozotocin-in-
duced oxidative stress and DNA dam-
ages in diabetic rats [38, 39]. In the
same model, they markedly decreased
plasma cholesterol, fasting insulin and
postprandial glucose levels. Improved
insulin sensitivity was associated with
increased levels of the glucose trans-
porter 4 (GLUT4) on the surface of
skeletal muscle cells [40]. Hypoglycemic
and hypolipidemic effects have been
also observed in alloxan-induced dia-
betic/hyperlipidemic rabbits [41]. In a
study performed with zeaxanthin di-
palmitate isolated from L. barbarum,
oral administration leads to a reduc-
tion of hepatic fibrosis induced by bile
duct ligation in rats. The antifibrotic
activity appears mediated at least in
part by the antioxidative activity [42].  
Immunomodulatory properties have
attracted much attention, also with re-
gard to cancer immunotherapy. LBP
have been shown in several studies to
promote splenocyte proliferation in
vitro [14,15,43]. There are evidences
that LBP act through enhanced ex-
pression of various cytokines and tran-
scription factors. The protein polysac-
charide complex LbGp4 stimulates the
expression of nuclear factor κB (NfκB)
and activator protein 1 (AP-1) [15].
LBP3 was shown to increase the ex-
pression of interleukin-2 (IL-2) and tu-
mor necrosis factor-α (TNF-α) at the
mRNA and protein levels in cultures of
human peripheral blood mononuclear
cells [44]. The immunostimulatory ac-
tivity appears to account for the anti-
tumour properties which have been de-
tected in mice. Thus, inhibition of
growth of S180 sarcoma tumors in
mice was correlated with increased
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macrophage phagocytosis, spleen lym-
phocyte proliferation, CTL activity and
IL-2 mRNA expression [45]. In addition
to immunostimulatory effects, propa-
poptotic properties may contribute to
the antitumour properties. LBP inhibit
cell proliferation with cell cycle arrest
in the S phase and induce apoptosis of
a human hepatoma cell line in vitro
[46]. Finally, hematopoietic properties
should be mentioned in the context of
a potential use as adjuvant in cancer
therapy. In irradiation- or chemother-
apy-induced myelsosuppressed mice,
LBP alleviates the decrease of red and
white blood cells [47].  
Another line of research has been
on neuroprotective properties. Oral pre-
treatment with an aqueous extract of
L. barbarum has been shown to protect
rat cortical neurons against Aβ-in-
duced toxicity. The underlying mecha-
nism appears to involve inhibition of
the Aβ-triggered c-Jun N-terminal ki-
nase (JNK) signaling pathway [48]. In-
terestingly, L. barbarum extract also
protects against reducing stress in-
duced by dithiothreitol which indicates
that the neuroprotective activity is not
merely due to antioxidative properties
[49]. The authors also observed re-
duced activity of caspases 3 and 2 and
inhibition of phosphorylation of dou-
ble-stranded RNA-dependent protein
kinase (PKR). Neuroprotective effects
have been also investigated in an ocu-
lar hypertension model of glaucoma.
Rats fed with an aqueous extract of L.
barbarum showed a strong reduction
of the loss of retinal ganglion cells. It
is noteworthy that the intraocular
pressure was not altered by the treat-
ment [51].
While there has been less investiga-
tion of the fruit of L. chinense, its bio-
logical properties appear to be basi-
cally similar. Noteworthy are anti-in-
flammatory properties on carragenan-
induced paw edema and hepatopro-
tective activity against CCl4-induced
liver damage in rat [52].
Clinical studies
Clinical studies have been almost ex-
clusively performed in China and have
focussed on age-related conditions.
Unfortunately, studies were mostly
small-sized and not adequately con-
trolled. Moreover, original data are
hardly accessible. In a representative
study with 42 in average 68 years old
participants, consumption of 50 mg of
wolfberry extract twice a day over two
months decreased dizziness, fatigue,
chest distress, sleep problem and
anorexia [53] (cited in [6]). However,
statistical significance was not as-
sessed in the study. In another study,
ingestion of 50 g/d of Goji berries in 25
elderly people for 10 days increased
SOD and hemoglobin and decreased
blood lipids significantly [54] (cited in
[6]). Recently, in a first double-blind
study performed outside China, the
general effects of GoChi™, a commer-
cial Goji juice, were investigated in
young healthy adults. Different para-
meters were assessed by a question-
naire. Blood pressure and body weight
were also monitored. The study con-
cludes that consumption of GoChi™ for
14 days increases subjective feelings of
general well-being and improves neu-
rologic performance as well as gas-
trointestinal function [55]. However,
the small size of the study (N=34) and
the subjectivity of most parameters
must be critically pointed out.
The potential effect of Goji as adju-
vant in cancer therapy has been in-
vestigated in a clinical study conducted
in China on 75 advanced cancer pa-
tients. A combination of IL-2/lympho-
kine-activated killer (LAK) therapy and
L. barbarum polysaccharides afforded
significantly higher response rates and
longer remission rates than IL-2/LAK
therapy alone [56]. 
While there are no studies demon-
strating the effect of the intake of Goji
itself for the prevention of age-related
eye diseases, there are many lines of
evidence supporting the protective role
of zeaxanthin. Thus, reduced incidence
of cataract and macular degeneration
has been associated with the intake of
leafy green vegetables which constitute
a rich source of zeaxanthin and lutein
[6,57,58]. A study with twelve volun-
teers who received free or esterified
carotenoids extracted from Goji berries,
suspended in a yoghourt, confirmed
the absorption of zeaxanthin. More-
over, the study indicated a strongly en-
hanced bioavailability of zeaxynthin
diplamitate, the dominating carotenoid
in Goji fruit, compared with the non-
esterified form [59]. 
Toxicology
and adverse reactions
Traces of atropine detected in the fruit
have no toxicological relevance and
there is no risk with cultivated plants.
In this context, the classification of the
plant as toxic [60,61] appears un-
funded. The LD50 of a water extract of
Goji berries was reported as 8.32 g/kg
by subcutaneous application in mice
[62] and confirms the virtual absence
of toxicity of the fruit. On the other
hand, some caution is advised with
samples of unknown origin since con-
fusion with morphologically similar
Solanaceous fruits can not be ruled out.
Such confusion may in fact explain
some contradictory data regarding the
alkaloid content of Goji berries. 
Despite the very long history of tra-
ditional use as food and herbal medi-
cine, there are practically no reports of
adverse effects due to Goji fruits. Only
a few cases of allergic reactions includ-
ing urticaria-like or papular rashes
have been documented [8]. In Chinese
medicinal books, some caution is ad-
vised to pregnant women. Also it is rec-
ommended that patients suffering from
diarrhea, fever, arthritis and strong in-
flammatory conditions should avoid
the consumption of the fruit [9,11,63].
However, no rationale is given as to
substantiate this recommendation. 
While the fruit appears devoid of
any acute toxicity, attention should be
paid to potential drug interactions, as
shown by a case report documenting a
possible interaction with warfarin. A
61-year old Chinese woman stabilized
on warfarin developed elevated inter-
national normalized ratio (INR) after
having drunk a tea of Goji berries over
four days. The value returned to nor-
mal after discontinuing the tea [64].
Weak inhibition of CYP2C9 was de-
tected in vitro (Ki of 3.4 mg/mL). How-
ever, the rather high value of the dis-
sociation constant suggests that other
mechanisms account for the drug in-
teraction in vivo. Considering the in-
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sufficient data, patients under medica-
tion should not consume Goji-derived
food supplements without informing
their physician.
Legal status
and market situation
Goji is commonly referred to as “Hi-
malayan Goji berry" or "Tibetan Goji
berry” on the global functional food
market. The variety of commercialized
products is considerable (Fig. 2): Be-
sides juices, wines and beers, Goji is
found in cookies, crispy bars, choco-
late, müsli, sausages and soaps. Goji
products have been marketed via In-
ternet since 2002 [4]. In Switzerland,
Goji products are also available in a
few drugstores, “Reformhäuser” or
“Bioladen”. Goji products are quite ex-
pensive with 30–50 Dollars to be paid
in average for a 1L bottle on the inter-
net market. A probably decisive factor
for the commercial success of Goji in
Western countries has been a booklet
of DR. EARL MINDELL entitled, “Goji, The
Himalayan Health Secret” [65]. Dr.
Mindell is a somewhat controversial
Canadian-American nutritionist who
has written several books on food sup-
plements and nutrition for the public.
His theories on health and nutrition
have met with deep scepticism in the
scientific community. In his book, he
extrapolates broad recommendations
of uses for Goji juice, including cancer
prevention, cardiovascular health, treat-
ment of diabetes and obesity (Table 2),
from traditional practices and prelim-
inary studies performed in China. In
particular, he claims quasi-miraculous
effects on life expectancy for Goji iden-
tified as “the Himalayan longevity fruit”.
Dr. Mindell and his statements about
the “extraordinary value” of Goji are
abundantly cited in advertisements for
Goji products, in particular by his part-
ner company FreeLife International
which distributes Gogi juice via multi-
level marketing. The health benefits
claimed by Dr. Mindell and to be found
in the web publications of the Goji man-
ufacturers were individually and criti-
cally reviewed in a recent book on wolf-
berry [66]. The authors conclude that
there are no scientific evidence and
peer-reviewed proofs to validate any of
the claims. One of the last products
launched by FreeLife International is
GoChi™, a juice claimed to contain
over 30% more bioactive polysaccha-
rides. The name GoChi is a combina-
tion of go from Goji and the Chinese
word chi meaning life energy. The ad-
vertising for this product draws on a
recent clinical study supposed to demon-
strate the product’s general effects on
health [55]. However, considering the
highly subjective parameters, the small
number of participants and the rela-
tively short-term study, the significance
of the data appears highly questionable.
Goji berries and Goji products are
legally sold as food or food supplements
in the USA and in Europe. However,
therapeutic claims are not allowed and
the products should not be promoted
as drugs. Thus in 2006, the FDA sent
warning letters to some Goji juice dis-
tributors because their marketing claims
violated the Food Drug and Cosmetic
Act [67,68]. In Europe, the UK Food
Standards Agency started an evalua-
tion procedure in 2007 to establish
whether Goji berries should receive the
status of Novel Food which would have
affected its authorization status for
sale. Thus, according to the EU Novel
Foods Regulation, new foods must be
demonstrated to be not unsafe, their
labeling to be not misleading and their
nutritional quality to be not inferior to
similar foods that they could replace.
After reviewing the data, the agency
came to the conclusion that there were
sufficient records of alimentary use of
Goji in the UK before 1997, and that
the fruit consequently does not fall un-
der the novel food legislation [69]. 
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Fig. 2. Goji berries and Goji juice.
Tab. 2. Goji as an expensive “cure-all”: recom-
mended uses for Goji juice and daily dose [65]
■ Allergies (60–120 ml)
■ Anti-aging (60–120 ml)
■ Arthritis and
inflammatory conditions (120 ml)
■ Cancer prevention (60 ml)
■ Cancer management (120–240 ml)
■ Cardiovascular health (120 ml)
■ Diabetes Type 2 (60 ml)
■ Hypertension (90 ml)
■ Immunity enhancement
(60–120 ml)
■ Infertility (150 ml for four months)
■ Liver protection (30–60 ml)
■ Obesity (60 ml, afternoon)
■ Sexual dysfunction (80–120 ml)
Average price
of a 1L bottle of Goji juice: 30–50 $ 
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Conclusions
Goji berries have a very long tradition
of use as food and traditional medicine
in China and other Asian countries.
Pharmacological investigations and
preliminary clinical data suggest that
the fruit may have beneficial proper-
ties, in particular in the prevention of
age-related ailments including neu-
rodegenerative diseases, type 2 dia-
betes and atherosclerosis. The poly-
saccharide fraction and the high con-
tent of zeaxanthin dipalmitate appear
to account at least in part for the bio-
logical properties. At the same time,
there is no scientific evidence support-
ing the health claims attributed to
pricey Goji products that are distrib-
uted via Internet. While the tradition of
use of this fruit over a long time with-
out any significant report of toxicity
demonstrates its safety in the context
of a normal consumption, caution is
advised with poorly controlled prod-
ucts consumed in amounts and forms
which have no relation with the tradi-
tional use. In addition, adulteration
may be an issue for food supplements
of undefined origin. Particular caution
is also recommended with patients un-
der medication, as underlined by a
case of possible interaction with war-
farin. 
In conclusion, while the Goji fruit
may possess interesting biological prop-
erties, further studies are indispens-
able before any recommendation of use
can be made for Goji products. Phar-
macological studies should in particu-
lar address possible drug interactions.
Large and controlled clinical studies
are required before the real potential
of Goji for prevention of chronic dis-
eases can be definitively assessed. Fi-
nally, there is also an urgent need to
establish quality standards for Goji
products for assessment of safety and
equivalence of commercial products. 
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